To Evaluate Efficacy of Ashwagandhadi Churna in the Management of Tamak Shwasa

An Open Labelled Active-controlled Randomized Clinical Study To Evaluate The Efficacy Of Ashwagandhadi Churna In Tamak Shwasa With Special Reference to Bronchial Asthma - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/04/084547

Enrollment

Registered

2025-04-11

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J459- Other and unspecified asthma

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patients diagnosed with well controlled and partly controlled Bronchial Asthma as per GINA 2024 Guideline of Bronchial Asthma Patients with Prebronchodilator FEV1 of Greater than 60 Percentage of the predicted value Patient willing to sign the informed consent and can participate in the study procedure

Exclusion criteria

Exclusion criteria: Pregnant or lactating women Known cases of Diabetes, uncontrolled hypertension, heart disease, secondary severe infections, Pleural effusion, pneumonia and pneumothorax, etc. Uncontrolled Bronchial Asthma as per GINA Guidelines 2024 Severe Bronchial Asthma as per GINA Guidelines 2024 Patients with Prebronchodilator FEV1 Less than 60 Percentage of the predicted value History of upper or lower respiratory tract infection, within the previous 30 days History of lung resection of more than one full lobe Have a known sensitivity to formoterol, ipratropium, and salbutamol etc medicine Immunocompromised status such as HIV, tuberculosis, cancer, etc

Design outcomes

Primary

Measure	Time frame
To assess Immunomodulatory and Bronchodilator effect of Ashwagandhadi Churna in the managemnet of Bronchial Asthma on the basis of spirometry of GINA Guidelines 2024Timepoint: Spirometry-On Screening visit and 60th day	—

Secondary

Measure	Time frame
To assess Immunomodulatory and Bronchodilator effect of Ashwagandhadi Churna in the managemnet of Bronchial Asthma on the basis of IgE,WBC and Asthma Control QuiestionnaireTimepoint: IgE-On Screening visit and 60th day WBC-On Screening visit and 60th day Asthma Control Quiestionnaire-On Screening visit , 15TH days, 30TH days, 45TH days sand 60th day	—

Countries

India

Contacts

Public ContactDr Manu R

Parul Institute of Ayurved

manu.r260022@paruluniversity.ac.in8160858967

Outcome results